Continuous cardiac output and hemodynamic monitoring: high temporal correlation between plasma TNF-α and hemodynamic changes during a sepsis-like state in cancer immunotherapy

Abstract

Through continuous cardiac output monitoring, we investigated the temporal relationship between hemodynamic changes and plasma cytokines in a cancer patient who developed collateral sepsis to immunotherapy. A 52-year-old male with metastatic renal cell carcinoma received interleukin-2 (IL-2) infusion completing 72 h of administration. The patient developed 3 sepsis-like states including systemic inflammatory response syndrome (SIRS), shock, and multiple organ dysfunction syndrome (MODS). Hemodynamic parameters including systemic vascular resistance index (SVRI), left ventricular stroke work index (LVSWI) and cardiac index (CI) were measured over 60 h. Peripheral blood was drawn when SVRI dropped 20% in the patient and plasma cytokines including TNF-α , IL-6 and IL-1β were measured using ELISA. After 60 h of immunotherapy, the patient showed a 63.4% decrease in SVRI, 54.5% decrease in LVSWI and 65.4% increase in CI. The evaluation of systemic cytokines revealed different kinetic patterns: (i) a sustained increase in TNFα levels through all 3 sepsis-like states; (ii) IL-6 increased preferentially during SIRS and shock, while up/down-responses were found during MODS; (iii) IL-1β was undetectable during the entire study period. A high temporal relationship between hemodynamic changes and plasma TNF-α, but not IL-6, was found. Although there are factors other than cytokines that can alter vascular resistance, this finding could represent an approach to evaluate the course of hemodynamia and probably the systemic cytokine expression after IL-2 administration in renal cancer.

References

Rosenberg SA , Yang JC , Topalian SJ et al. The treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2 . JAMA 1994; 271: 907—913.

Law TM , Motzer RJ , Mazumdar M. et al. Phase III randomized trial of interleukin-2 with or without lymphokine activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824—832.

Diana D. , Sculier JP Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 (ala-125) in patients with advanced cancer. Intensive Care Med 1990; 16: 167—170.

Seelen F. , Lampert R. , Brandt L. Hyperdynamic hemodynamics following high-dose interleukin-2, interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model. Anaesthesist 1996 ; 45: 1171—1178.

Muñoz C. , Misset B. , Fitting C. , Blériot JP , Carlet J. , Cavaillon JM Dissociation between plasma and monocyte-associated cytokines during sepsis . Eur J Immunol 1991; 21: 2177—2184.

Muñoz C. , Carlet J. , Fitting C. , Misset B. , Blériot JP , Cavaillon JM Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88: 1747—1754.

Girardin E. , Grau GE , Dayer JM , Roux-Lombard P. , The J5 Study Group, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397—400.

Dinarello CA Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44:153—205.

Hack CE , De Groot ER , Felt Bersma RJ , Nuijens JH Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704—1710.

10.

Waage A. , Brandtzag P. , Halstensen A. , Kierulf P. , Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock, association between interleukin-6, interleukin-1 and the fatal outcome. J Exp Med 1989; 169: 333—338.

11.

Cannon JG , Tompkins RG , Gelfand JA et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79—84.

12.

Calandra T. , Baumgarter JD , Gram EG et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161: 982—987.

13.

Hoch RC , Rodriguez R. , Manning T. et al. Effects of accidental trauma on cytokine and endotoxin production . Crit Care Med 1993; 21: 839—845.

14.

Bone RC Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163—172.

15.

Cavaillon JM , Muñoz C. , Fitting C. Misset B , Carlet J. Circulating cytokines: the tip of the iceberg. Circ Shock 1992; 38: 145—152.

16.

Beal AL , Cerra FB Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA 1994; 271: 226—233.

17.

Boldt J. , Menges T. , Wollbruck M. , Hammermann H. , Hempelmann G.

Is continuous cardiac output measurement using thermodilution reliable in the critically ill patient?

Crit Care Med 1994; 22: 1913—1918.

18.

Haller M. , Zollner C. , Briegel J. , Forst H. Evaluation of a new continuous thermodilution cardiac output monitor in critically ill patients: a prospective criterion standard study. Crit Care Med 1995; 22: 860—866.

19.

Burchell SA , Yu M. , Takiguchi SA , Otha RM , Myers SA Evaluation of continuous cardiac output and mixed venous oxygen saturation catheter in critically ill surgical patients . Crit Care Med 1997; 25: 388—391.

20.

Negrier S. , Escudier B. , Lasset C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272—1278.

21.

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and multiple organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 23: 1638—1652.

22.

Medin DL , Brown DT , Wesley R. , Cunnion RE , Ognibene FP Validation of continuous thermodilution cardiac output in critically ill patients with analysis of a systematic errors. J Crit Care 1998; 13: 184—189.

23.

Motzer RJ , Bander NH , Nanus DM Renal-cell carcinoma. N Engl J Med 1996; 335: 865—875.

24.

Lee RE , Lotze MT , Skibber JM et al. Cardiorespiratory effects of immunotherapy with interleukin-2 . J Clin Oncol 1989; 7: 7—20.

25.

Marie C. , Fitting C. , Cheval C. et al. Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome. Infect Immun 1997; 65: 865—871.

26.

Zwaveling JH , Maring JK , Clarke FL et al. High plasma tumor necrosis factor (TNF- α) concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF- α, interferon-γ, and mephalan. Crit Care Med 1996; 24: 765—770.